Fundraising Fox
Kyverna Therapeutics
NASDAQ: KYTXEmeryville, US · Founded 2018 · 174 employees on LinkedIn · 10 known investors
Find your way into Kyverna Therapeutics
Sign up to see every warm intro you have to Kyverna Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kyverna Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Founders & leadership
Investors · 10
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
How we know: Vida Ventures's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us
How we know: Westlake Village BioPartners's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Funding
SEC filings, press & company announcements$152M disclosed across 1 of 3 rounds · 1900–2021
- Undisclosed amountSeries AJan 2020Source ↗
▶$152MraisedNov 2023 · 24 investors · BiotechnologyRule 506(b)
- Brian KotzinDirector
- Ian ClarkDirector
- Ryan JonesExecutive Officer
- Karen WalkerExecutive Officer
- Peter MaagExecutive Officer, Director
- James ChungExecutive Officer
- Dan SpiegelmanDirector
- Beth SpiegelmanDirector
- Fred CohenDirector
- Steve LiapisDirector
- Dominic BorieExecutive Officer
- Offering amount
- $152M
- Amount sold
- $152M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 1
Companies working in the same space as Kyverna Therapeutics.
In the news
Kyverna Therapeutics to Present at Upcoming September 2026 Investor Conferences - BioSpacebiospace.com · Sep 2026Frequently asked questions
- What does Kyverna Therapeutics do?
- Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
- Who are Kyverna Therapeutics's investors?
- Kyverna Therapeutics's investors include Bain Capital Life Sciences, Vida Ventures, Westlake Village BioPartners, Gilead Sciences, Insight Partners, Kleiner Perkins, Northpond Ventures, Oxford Finance LLC and 2 more.
- How much funding has Kyverna Therapeutics raised?
- Kyverna Therapeutics has disclosed $152M raised across 1 of its 3 known rounds.
- Where is Kyverna Therapeutics headquartered?
- Kyverna Therapeutics is headquartered in Emeryville, US.